Neuroleptic malignant syndrome complicating closed head injury.
Lethargy, hyperpyrexia, tremor, and rigidity associated with leukocytosis and elevation of the creatine kinase level occurred in a patient with a closed head injury who was being treated with haloperidol for control of agitation. This constellation of symptoms, known as the neuroleptic malignant syndrome (NMS), partially improved when the neuroleptic medication was stopped, but complete resolution of the syndrome did not occur until the patient was treated with bromocriptine. Because haloperidol is the most widely used medication for the agitation that develops in patients with significant closed head injuries, neurosurgeons should be aware of the NMS. The NMS is caused by neuroleptic medications and may initially present with unexplained hyperpyrexia, leukocytosis, and elevated creatine kinase levels. Halting the neuroleptic, supportive care, and the use of dantrolene sodium and bromocriptine are the treatment modalities of choice for this syndrome, which has a mortality rate of 20 to 30% and may be linked to malignant hyperthermia.
D000328:Adult; D001930:Brain Injuries / Q000150:complications*; D001971:Bromocriptine / Q000627:therapeutic use*; D006220:Haloperidol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000150:complications* / Q000188:drug therapy / Q000209:etiology; D011595:Psychomotor Agitation / Q000188:drug therapy; D014949:Wounds, Nonpenetrating / Q000150:complications*
D001971:Bromocriptine; D006220:Haloperidol